1. Home
  2. MREO vs PGC Comparison

MREO vs PGC Comparison

Compare MREO & PGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MREO
  • PGC
  • Stock Information
  • Founded
  • MREO 2015
  • PGC 1921
  • Country
  • MREO United Kingdom
  • PGC United States
  • Employees
  • MREO N/A
  • PGC N/A
  • Industry
  • MREO Biotechnology: Pharmaceutical Preparations
  • PGC Commercial Banks
  • Sector
  • MREO Health Care
  • PGC Finance
  • Exchange
  • MREO Nasdaq
  • PGC Nasdaq
  • Market Cap
  • MREO 424.5M
  • PGC 487.4M
  • IPO Year
  • MREO N/A
  • PGC N/A
  • Fundamental
  • Price
  • MREO $2.85
  • PGC $26.60
  • Analyst Decision
  • MREO Strong Buy
  • PGC Strong Buy
  • Analyst Count
  • MREO 7
  • PGC 2
  • Target Price
  • MREO $7.71
  • PGC $38.50
  • AVG Volume (30 Days)
  • MREO 1.2M
  • PGC 68.7K
  • Earning Date
  • MREO 08-12-2025
  • PGC 07-22-2025
  • Dividend Yield
  • MREO N/A
  • PGC 0.75%
  • EPS Growth
  • MREO N/A
  • PGC N/A
  • EPS
  • MREO N/A
  • PGC 1.80
  • Revenue
  • MREO N/A
  • PGC $227,831,000.00
  • Revenue This Year
  • MREO N/A
  • PGC $29.32
  • Revenue Next Year
  • MREO $54.07
  • PGC $17.18
  • P/E Ratio
  • MREO N/A
  • PGC $14.77
  • Revenue Growth
  • MREO N/A
  • PGC 9.82
  • 52 Week Low
  • MREO $1.58
  • PGC $20.80
  • 52 Week High
  • MREO $5.02
  • PGC $37.88
  • Technical
  • Relative Strength Index (RSI)
  • MREO 64.74
  • PGC 39.73
  • Support Level
  • MREO $2.61
  • PGC $26.45
  • Resistance Level
  • MREO $2.85
  • PGC $28.52
  • Average True Range (ATR)
  • MREO 0.17
  • PGC 0.68
  • MACD
  • MREO 0.03
  • PGC -0.13
  • Stochastic Oscillator
  • MREO 88.83
  • PGC 10.14

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

About PGC Peapack-Gladstone Financial Corporation

Peapack Gladstone Financial Corp provides banking services. It operates through two segments namely Banking, which involves the delivery of loans and deposits, and Wealth Management Division which includes asset management services. The banking segment includes commercial real estate, multifamily, residential and consumer lending, deposit generation, and Internet banking services. Wealth Management includes investment management services for individuals and institutions; personal trust services, administrator, custodian and guardians, and other financial planning and advisory services. The services provided by the company include checking and savings accounts, money market and interest-bearing checking accounts, certificates of deposit, individual retirement accounts, and other services.

Share on Social Networks: